Nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC in the real-world setting: Safety results of the non-interventional NEPTUN study.

Dechow, T., Riera-Knorrenschild, J., Hackanson, B., Fischer von Weikersthal, L., Chiabudini, M., Timm, B., Zerbes, R.M., Potthoff, K., 2020.

Oncol Res Treat 43 (suppl 1)(276), 112.